Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...
The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...
High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...
A negative scan does not always mean recurrent prostate cancer is nowhere to be found. Sometimes, the disease may simply be ...
For men with a localized recurrence following prostate cancer radiotherapy, salvage treatment with either focal therapy or surgery may offer comparable long-term cancer control, but focal therapy ...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...
An NHS trial over 10 years followed nearly 3,500 men who received focal therapy, a less invasive treatment.
Add Yahoo as a preferred source to see more of our stories on Google. Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare ...
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare two types of targeted radiation therapy for men with recurrent prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results